Status:
COMPLETED
Patency and Safety of the Drug Eluting Covered Biliary Stent Comparing to the Common Covered Biliary Stent
Lead Sponsor:
Taewoong Medical Co., Ltd.
Conditions:
Biliary Stricture
Malignant Neoplasms
Eligibility:
All Genders
19-90 years
Phase:
NA
Brief Summary
Paclitaxel covered metal biliary stent extents their patency rate comparing to the Common Covered Metallic Biliary Stent.
Detailed Description
Paclitaxel covered metal biliary stent(Mira-Cover Biliary Stent) extents their patency rate comparing to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent.
Eligibility Criteria
Inclusion
- Patient who is inoperable and/or unresectable cases of pancreatic cancer and/or biliary cancer with mid or distal CBD invasion
- Among patient of a.,Patient who previously had surgical biliary drainage of plastic stent have eligibility
Exclusion
- Patient who have life expectancy under 3 months
- Patient who have severe metastasis of Liver or whole body
- Patient who previously had surgical biliary drainage
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT01512563
Start Date
February 1 2007
End Date
February 1 2010
Last Update
March 11 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Soon Chun Hyang University Hospital Cheonan
Cheonan, South Korea
2
Catholic University of Daegu School of Medicine
Daegu, South Korea
3
Kangnam Severance Hospital
Seoul, South Korea, 135-720